Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

February 28, 2013

Conditions
T-cell Lymphoma
Interventions
DRUG

Bendamustine

Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles

Trial Locations (1)

80054

Dr Gandhi DAMAJ, Amiens

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mundipharma Pte Ltd.

INDUSTRY

lead

French Innovative Leukemia Organisation

OTHER

NCT00959686 - Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma | Biotech Hunter | Biotech Hunter